Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Chinese Patent Office

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 5,229,382

« Back to Dashboard

Summary for Patent: 5,229,382

Title: 2-methyl-thieno-benzodiazepine
Abstract:2-Methyl-10-(4-methyl-1-piperazinyl)-4H-thieno-[2,3-b][1,5]benzodiazepine, or an acid salt thereof, has pharmaceutical properties, and is of particular use in the treatment of disorders of the central nervous system. The compound has the following structure: ##STR1##
Inventor(s): Chakrabarti; Jiban K. (Frimley, GB2), Hotten; Terrence M. (Farnborough, GB2), Tupper; David E. (Reading, GB2)
Assignee: Lilly Industries Limited (Basingstoke, GB2)
Application Number:07/890,348
Patent Claim Types:
see list of patent claims
Compound; Composition; Dosage form; Use; Formulation;

No matches for this query

Foreign Priority and PCT Information for Patent: 5,229,382

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9009229Apr 25, 1990

International Patent Family for Patent: 5,229,382

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Finland101379► Subscribe
Finland971316► Subscribe
Germany69112895► Subscribe
Denmark0454436► Subscribe
European Patent Office0454436► SubscribeCA 2001 00042Denmark► Subscribe
European Patent Office0454436► SubscribeC970015Netherlands► Subscribe
European Patent Office0454436► SubscribeSPC/GB96/058United Kingdom► Subscribe
European Patent Office0454436► Subscribe97C0012Belgium► Subscribe
European Patent Office0454436► Subscribe9/1997Austria► Subscribe
Spain2078440► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch: